![]()
Biotech Industry
The latest biotech headlines from MarketWatch.
Merck and Moderna launch late-stage trial of V940 with Keytruda as treatment for high-risk melanoma
Merck & Co. MRK and Moderna Inc. MRNA said Wednesday they have launched a Phase 3 trial of Moderna’s V940 in combination with Merck’s Keytruda as a...
Immatics shares jump after investment from Bristol Myers Squibb
Shares of Immatics N.V. IMTX gained more than 8% premarket on Monday after the clinical-stage biopharma company said it had received a $35 million ...
Kodiak Sciences stock plunges into record-low territory after decision to discontinue wet AMD treatment
Shares of Kodiak Sciences Inc. KOD plummeted 56.9% into record-low territory, and to pace all premarket declines, after the California-based biotec...
Most Popular
More Biotech Headlines
These 13 S&P 500 stocks stand out for expected growth through 2025
Some big numbers have been baked into estimates for 2023. Looking out another two years can highlight opportunities in the stock market.
COVID pandemic is officially over in the U.S., excess-deaths data show
The COVID-19 pandemic is definitively over, according to two recent reports focused on the same metric.
RedHill Biopharma shares erase gains after company announces stock offering
The stock gained early Friday on news of fresh U.S. government funding for a treatment for radiation sickness, but the move was derailed by a stock offering.
Turnstone Biologics set to go public as upsized $80 million IPO pricing at low end of expected range
Turnstone Biologics Corp. TSBX is headed for its public debut Friday, as the San Diego-based biotechnology company focused on treating tumors raised $80 million through an upsized initial public offering. The company said ...
Mirati Therapeutics shares fall after lung cancer drug gets negative opinion from European regulators
Shares of Mirati Therapeutics Inc. MRTX were down 4.7% premarket on Friday after the company said the European Medicines Agency had issued a negative opinion on a marketing application for Krazati, a treatment for non-smal...
Vir Biotechnology’s stock slides 40% after it says mid-stage trial of a flu treatment failed to meet main goals
Vir Biotechnology Inc. VIR said Thursday a mid-stage trial of a treatment for symptomatic flu failed to meet its main goals, sending the stock down 40% premarket. The Phase 2 trial dubbed Peninsula was evaluating VIR-2482 ...
Legend Biotech shares gain on multiple-myeloma drug sales
Shares of Legend Biotech Corp. LEGN gained 3.7% premarket on Thursday after the company said its multiple myeloma therapy Carvykti, a collaboration with Johnson & Johnson JNJ, generated $117 million in sales in the second ...
Eliem Therapeutics’ stock soars 21% premarket after company says it may sell itself
Eliem Therapeutics Inc.’s stock ELYM soared 21% in premarket trade Thursday, after the biotech, which specializes in therapies for neuronal excitability disorders, said it is exploring its strategic options. The Seattle an...
At-home Alzheimer’s testing is on the horizon, researchers say
Early detection, regular monitoring are key, experts say, as new Alzheimer’s treatment options emerge
Advanced Biomed sets IPO terms, which could value the biotech at up to $625 million
Advanced Biomed Inc. ADVB has set terms for its initial public offering, in which the Taiwan-based biotechnology company focused on treating cancer is looking to raise up to $125 million. The company said it is offering 25...
Pardes Biosciences stock rallies on buyout offer from MediPacific
Pardes Biosciences Inc.’s PRDS stock was up 12.4% in premarket trades Monday after the clinical-stage biopharmaceutical company said it agreed to be acquired by MediPacific Inc. for up to $2.19 a share. The purchase price ...
BridgeBio’s stock rockets 66% on news of positive results from late-stage trial of ATTR-CM treatment
BridgeBio Pharma Inc.’s stock BBIO rocketed 66% in premarket trade Monday, after the company announced positive results in a late-stage trial of a treatment for transthyretin amyloid cardiomyopathy, or ATTR-CM, a buildup ...
Turnstone Biologics to offer 5.8 million shares in planned IPO priced at $12 to $14 each
Turnstone Biologics TSBX, a clinical-stage biotech that specializes in treatments for solid tumors, set terms for its initial public offering on Monday with plans to offer 5.8 million shares priced at $12 to $14 each. The ...
Redlining was outlawed 55 years ago, but it’s still hurting heart health today
Living in a formerly redlined neighborhood is linked to higher risk of stroke, heart attack and other cardiovascular emergencies, a new study says.
Roivant stock rallies on report of pending drug sale: WSJ
Shares of Roivant Sciences Ltd. ROIV surged in the extended session Thursday following a report that Roche Holding CH:ROG was close to buying an experimental drug from the biotech company. Roivant shares surged 10% after h...
Theseus Pharmaceuticals stock plummets after cancer drug development stopped
Theseus Pharmaceuticals Inc. THRX shares plummeted after hours Thursday after the biotech drug maker discontinued enrolling patients in the study of a cancer drug it no longer intend to develop. Theseus shares plunged as m...
Caribou Biosciences offers more stock, and shares fall
Shares of Caribou Biosciences Inc. CRBU tumbled 9.7% after hours on Thursday after the biopharma company said it had begun a $100 million share offering. The company, which focuses on genome editing, said it would grant th...
Recursion Pharmaceuticals stock soars following $50 million investment from AI chipmaker Nvidia
Recursion Pharmaceuticals Inc. RXRX shares soared Wednesday after the drug developer said that graphics processing unit maker Nvidia Corp. NVDA invested $50 million in the company to boost drug discovery efforts using arti...
Liminal BioSciences stock rockets on take-private deal with a fund managed by Thomvest Asset Management
Liminal BioSciences Inc. LMNL stock is rallying 41.7% in premarket trades on Wednesday after the company said it agreed to go private at a price of $8.50 a share. Structured Alpha LP, a fund managed by Thomvest Asset Mana...
Priveterra Acquisition says it will list on NYSE after AEON combination
Priveterra Acquisition, a special purpose acquisition company, currently trades on the Nasdaq.
